ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has received a consensus recommendation of “Buy” from the four research firms that are presently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $80.00.
A number of research firms have weighed in on ANIP. Truist Financial upped their price target on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, March 1st. HC Wainwright raised their price target on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a report on Monday, March 4th. Capital One Financial assumed coverage on shares of ANI Pharmaceuticals in a report on Friday, March 15th. They issued an “overweight” rating and a $80.00 price objective on the stock. Finally, Guggenheim restated a “buy” rating and set a $77.00 target price on shares of ANI Pharmaceuticals in a research note on Tuesday, April 23rd.
Read Our Latest Research Report on ANIP
Insider Activity at ANI Pharmaceuticals
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. boosted its position in ANI Pharmaceuticals by 93.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 248 shares during the period. BluePath Capital Management LLC bought a new stake in ANI Pharmaceuticals in the third quarter valued at $34,000. Pacer Advisors Inc. acquired a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at $41,000. AJOVista LLC bought a new position in shares of ANI Pharmaceuticals during the fourth quarter worth about $58,000. Finally, SG Americas Securities LLC bought a new position in shares of ANI Pharmaceuticals during the first quarter worth about $106,000. 76.05% of the stock is currently owned by institutional investors.
ANI Pharmaceuticals Price Performance
ANIP opened at $65.62 on Friday. The company has a 50 day moving average of $66.96 and a two-hundred day moving average of $59.36. ANI Pharmaceuticals has a 52-week low of $38.91 and a 52-week high of $70.81. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66. The company has a market cap of $1.38 billion, a P/E ratio of 78.12 and a beta of 0.80.
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. The firm had revenue of $131.65 million during the quarter, compared to analysts’ expectations of $123.02 million. On average, analysts expect that ANI Pharmaceuticals will post 3.55 earnings per share for the current year.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
See Also
- Five stocks we like better than ANI Pharmaceuticals
- Best Aerospace Stocks Investing
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- What is the FTSE 100 index?
- Generac Powers Ahead on the Electrification Mega-Trend
- Airline Stocks – Top Airline Stocks to Buy Now
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.